We are live on ! Find out more
EPRS

EPIRUS BIOPHARMACEUTICALS INC COM
EPRS

Delisted

EPRS was delisted on the 3rd of August, 2016.

Back to rankings

41 hedge funds and large institutions have $64.9M invested in EPIRUS BIOPHARMACEUTICALS INC COM in 2015 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 41 → 41 (0)

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

20% less capital invested

Capital invested by funds: $81M → $64.9M (-$16.1M)

25% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 12

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $494K

Holders
41
Holders Change
–
Holders Change %
0%
% of All Funds
1.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
9
Reduced
12
Closed
11
Calls
–
Puts
$494K
Net Calls
-$494K
Net Calls Change
-$495K

Top Buyers

1
Millennium Management
Millennium Management
New York
+$2.23M
2
B
Bailard
California
+$796K
3
TC
TFS Capital
Pennsylvania
+$386K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$376K
5
CCM
Consonance Capital Management
New York
+$345K

Top Sellers

1
LOAMU
Lombard Odier Asset Management (USA)
New York
-$724K
2
BA
BlackRock Advisors
Delaware
-$393K
3
BIT
BlackRock Institutional Trust
California
-$304K
4
Citadel Advisors
Citadel Advisors
Florida
-$230K
5
Jennison Associates
Jennison Associates
New York
-$217K
Name Holding Trade Value Shares
Change 		Change in
Stake
SSG
51
Summit Securities Group
New York
– +$587 +100 New
1 2
3

EPRS Hedge Fund Activity: Q3 2015 in Review

41 of the 3,581 institutional investors tracked by Wall St. Rank reported a position in EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) for Q3 2015, worth a combined $64.9M — down 20% from $81M a quarter earlier.

Fund positioning in EPRS was balanced in Q3 2015: 11 funds opened new positions, 11 closed out, 9 added to existing stakes and 12 trimmed.

The largest buyer was Millennium Management, adding an estimated $2.23M. The largest seller was Lombard Odier Asset Management (USA), exiting entirely with an estimated $724K sold.

  • 41 institutional investors held EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) as of Q3 2015, unchanged from Q2 2015.
  • Funds reported $64.9M of EPIRUS BIOPHARMACEUTICALS INC COM stock for Q3 2015, down 20% quarter-over-quarter.
  • 11 funds opened new EPIRUS BIOPHARMACEUTICALS INC COM positions in Q3 2015 and 11 closed out, a net change of 0 holders.
  • The largest EPIRUS BIOPHARMACEUTICALS INC COM buyer in Q3 2015 was Millennium Management, an estimated $2.23M added.
  • The largest EPIRUS BIOPHARMACEUTICALS INC COM seller in Q3 2015 was Lombard Odier Asset Management (USA), an estimated $724K sold.

Based on aggregated 13F filings for Q3 2015.